BCL2L11 and non-small cell lung carcinoma: Moreover, in patients with EGFR-mutated NSCLC and BIM deletion polymorphisms, the combination of EGFR-TKI and pemetrexed or gemcitabine-based platinum doublet chemotherapy significantly improved the ORR (65.5% vs. 38.9%; p = 0.046) and prolonged the PFS (7.2 months vs. 4.7 months; p = 0.008) and OS (18.5 months vs. 14.2 months; p = 0.107) compared to EGFR-TKI treatment alone (Table 5) [78].